• LAST PRICE
    0.7237
  • TODAY'S CHANGE (%)
    Trending Down-0.0263 (-3.5067%)
  • Bid / Lots
    0.6800/ 6
  • Ask / Lots
    0.7400/ 15
  • Open / Previous Close
    0.7500 / 0.7500
  • Day Range
    Low 0.6847
    High 0.7500
  • 52 Week Range
    Low 0.4501
    High 1.5799
  • Volume
    20,122
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.75
TimeVolumeGRAY
09:32 ET1000.75
09:57 ET1000.73
10:27 ET1000.72
11:30 ET2010.75
01:24 ET20000.7201
01:26 ET27990.725
01:27 ET20000.725
01:29 ET18000.72
01:40 ET10000.707101
01:49 ET6000.7173
01:51 ET5510.7275
02:03 ET9000.7071
02:12 ET3750.7096
02:21 ET50000.69545
02:23 ET3880.6847
02:27 ET12000.6847
02:36 ET3000.6882
03:15 ET2000.7237
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGRAY
Graybug Vision Inc
16.2M
-0.4x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
16.1M
-0.7x
---
United StatesCEOS
CeCors Inc
15.8M
0.0x
---
United StatesNRBO
Neurobo Pharmaceuticals Inc
15.6M
-0.1x
---
United StatesNNVC
NanoViricides Inc
16.8M
-2.4x
---
United StatesBPTH
Bio Path Holdings Inc
17.3M
-1.1x
---
As of 2023-01-26

Company Information

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The Company's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The Company is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.

Contact Information

Headquarters
203 Redwood Shores Parkway, Suite 620REDWOOD CITY, CA, United States 94065
Phone
650-487-2800
Fax
302-655-5049

Executives

Independent Chairman of the Board
Christy Shaffer
President, Chief Executive Officer, Director
Frederic Guerard
Chief Financial Officer
Robert Breuil
Chief Medical Officer
Parisa Zamiri
Independent Director
Christina Ackermann

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$16.2M
Revenue (TTM)
$0.00
Shares Outstanding
21.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.72
Book Value
$3.04
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.